FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Azienda Ospedaliera Universitaria Pisana · University of Pisa · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,088
total citations
- FWCI
- 35.93
- Percentile
- 100%
- References
- 26
Citations per year
Authors
20- CCChiara Cremolini
Azienda Ospedaliera Universitaria Pisana, University of Pisa
- FLFotios Loupakis
Azienda Ospedaliera Universitaria Pisana, University of Pisa
- CACarlotta Antoniotti
University of Pisa, Azienda Ospedaliera Universitaria Pisana
- CLCristiana Lupi
University of Pisa
- ESElisa Sensi
University of Pisa
Topics & keywords
Topics
Keywords
- Bevacizumab
- FOLFIRI
- Medicine
- Irinotecan
- Fluorouracil
- Oxaliplatin
- Internal medicine
- Colorectal cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.